Locally Advanced Pancreatic Cancer Clinical Trial
Official title:
An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.
The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer
Patients with Locally Advanced Pancreatic Cancer who have not received prior treatment to their pancreatic cancer will be informed about the study and the potential risks and benefits. After providing informed consent patients will undergo a 3 week screening period to confirm eligibility for the study. Patients who meet all eligibility criteria will be randomised 1:1 to either the control arm of up to 12 cycles of standard of care FOLFIRINOX chemotherapy or implantation of OncoSil™ in addition to the same FOLFIRINOX chemotherapy regimen. Patients will be followed for side side effects and palliative benefits during 4-8 weekly study visits and the objective efficacy of the treatment will be assessed by CT scans every 8 weeks. Quality of Life will be measured on various time-points using questionnaires. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Completed |
NCT01628458 -
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04276857 -
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
|
N/A | |
Not yet recruiting |
NCT05988372 -
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
|
Phase 2 | |
Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT03126435 -
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
|
Phase 3 | |
Completed |
NCT02035072 -
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
|
Phase 2 | |
Enrolling by invitation |
NCT01063192 -
A Study of Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT06429904 -
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT03885219 -
Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03468335 -
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
|
Phase 3 | |
Not yet recruiting |
NCT03443921 -
Divestment for Artery-involved Pancreatic Cancer
|
N/A | |
Recruiting |
NCT03257033 -
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
|
Phase 3 | |
Completed |
NCT02578732 -
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
|
Phase 2 | |
Recruiting |
NCT04789980 -
Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
|
||
Completed |
NCT00644618 -
Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy
|
Phase 3 | |
Recruiting |
NCT03682289 -
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
|
Phase 2 | |
Terminated |
NCT02404363 -
Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy
|
Phase 3 | |
Active, not recruiting |
NCT06353581 -
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
|
Phase 2 | |
Not yet recruiting |
NCT03815461 -
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
|
Phase 2 |